Develop and implement capacity to monitor circulating tumor nucleic acid
Ended Awarded Last action
- Contract number
- HHSN26100010
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,490,899
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $4,490,899.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost No Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$4,739 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $46,936 | |
| Other Administrative Action | $0 | |
| Original award | $4,448,702 |
About this award
This is a $4,490,899.23 cost-no-fee Delivery Order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is to develop and implement capacity to monitor circulating tumor nucleic acid, with a period of performance ending on September 25, 2020. This contract is not associated with a set-aside program. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a range of biomedical research and facilities support services. Notable aspects of their work include COVID-19 research, GMP manufacturing of immunotoxins and vaccines, and support for the Clinical Proteomic Tumor Analysis Consortium program.
Quick answers
Who was awarded contract HHSN26100010?
HHSN26100010 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 26, 2015.
How much is contract HHSN26100010 worth?
The government has obligated $4,490,899 on HHSN26100010.
Is contract HHSN26100010 an order under another contract?
Yes. HHSN26100010 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100010 competed?
The extent of competition for HHSN26100010 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award